| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Pathology and Laboratory Medicine, and
Department of Medicine, Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, PA 19104; and
Department of Chemical and Environmental Engineering, University of California, Riverside, CA 92521
Regulation of complement activation by pathogens and the host are critical for survival. Using two highly related orthopoxvirus proteins, the vaccinia and variola (smallpox) virus complement control proteins, which differ by only 11 aa, but differ 1000-fold in their ability to regulate complement activation, we investigated the role of electrostatic potential in predicting functional activity. Electrostatic modeling of the two proteins predicted that altering the vaccinia virus protein to contain the amino acids present in the second short consensus repeat domain of the smallpox protein would result in a vaccinia virus protein with increased complement regulatory activity. Mutagenesis of the vaccinia virus protein confirmed that changing the electrostatic potential of specific regions of the molecule influences its activity and identifies critical residues that result in enhanced function as measured by binding to C3b, inhibition of the alternative pathway of complement activation, and cofactor activity. In addition, we also demonstrate that despite the enhanced activity of the variola virus protein, its cofactor activity in the factor I-mediated degradation of C3b does not result in the cleavage of the 
' chain of C3b between residues 954–955. Our data have important implications in our understanding of how regulators of complement activation interact with complement, the regulation of the innate immune system, and the rational design of potent complement inhibitors that might be used as therapeutic agents.
This article has been cited by other articles:
|
|
 |
|
  M. K. Liszewski, M. K. Leung, R. Hauhart, C. J. Fang, P. Bertram, and J. P. Atkinson Smallpox Inhibitor of Complement Enzymes (SPICE): Dissecting Functional Sites and Abrogating Activity J. Immunol., September 1, 2009; 183(5): 3150 - 3159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Thorgersen, A. Pharo, K. Haverson, A. K. Axelsen, P. Gaustad, G. J. Kotwal, G. Sfyroera, and T. E. Mollnes Inhibition of Complement and CD14 Attenuates the Escherichia coli-Induced Inflammatory Response in Porcine Whole Blood Infect. Immun., February 1, 2009; 77(2): 725 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Liszewski, P. Bertram, M. K. Leung, R. Hauhart, L. Zhang, and J. P. Atkinson Smallpox Inhibitor of Complement Enzymes (SPICE): Regulation of Complement Activation on Cells and Mechanism of Its Cellular Attachment J. Immunol., September 15, 2008; 181(6): 4199 - 4207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Girgis, B. C. DeHaven, X. Fan, K. M. Viner, M. Shamim, and S. N. Isaacs Cell Surface Expression of the Vaccinia Virus Complement Control Protein Is Mediated by Interaction with the Viral A56 Protein and Protects Infected Cells from Complement Attack J. Virol., May 1, 2008; 82(9): 4205 - 4214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. N. Yadav, K. Pyaram, J. Mullick, and A. Sahu Identification of Hot Spots in the Variola Virus Complement Inhibitor (SPICE) for Human Complement Regulation J. Virol., April 1, 2008; 82(7): 3283 - 3294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kimura, T. Miwa, L. Zhou, and W.-C. Song Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement Blood, January 15, 2008; 111(2): 732 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hammel, G. Sfyroera, S. Pyrpassopoulos, D. Ricklin, K. X. Ramyar, M. Pop, Z. Jin, J. D. Lambris, and B. V. Geisbrecht Characterization of Ehp, a Secreted Complement Inhibitory Protein from Staphylococcus aureus J. Biol. Chem., October 12, 2007; 282(41): 30051 - 30061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kuttner-Kondo, D. E. Hourcade, V. E. Anderson, N. Muqim, L. Mitchell, D. C. Soares, P. N. Barlow, and M. E. Medof Structure-based Mapping of DAF Active Site Residues That Accelerate the Decay of C3 Convertases J. Biol. Chem., June 22, 2007; 282(25): 18552 - 18562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Singh, J. Mullick, J. Bernet, and A. Sahu Functional Characterization of the Complement Control Protein Homolog of Herpesvirus Saimiri: ARG-118 IS CRITICAL FOR FACTOR I COFACTOR ACTIVITIES J. Biol. Chem., August 11, 2006; 281(32): 23119 - 23128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Liszewski, M. K. Leung, R. Hauhart, R. M. L. Buller, P. Bertram, X. Wang, A. M. Rosengard, G. J. Kotwal, and J. P. Atkinson Structure and Regulatory Profile of the Monkeypox Inhibitor of Complement: Comparison to Homologs in Vaccinia and Variola and Evidence for Dimer Formation J. Immunol., March 15, 2006; 176(6): 3725 - 3734. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
